{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T06:03:13Z","timestamp":1782540193303,"version":"3.54.5"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,9]],"date-time":"2019-11-09T00:00:00Z","timestamp":1573257600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7172140"],"award-info":[{"award-number":["7172140"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.apsb.2019.11.006","type":"journal-article","created":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T03:29:07Z","timestamp":1573702147000},"page":"276-288","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["A novel S1P1 modulator IMMH002 ameliorates psoriasis in multiple animal models"],"prefix":"10.1016","volume":"10","author":[{"given":"Jing","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinping","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dali","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoguang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuan","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2019.11.006_bib1","doi-asserted-by":"crossref","first-page":"16082","DOI":"10.1038\/nrdp.2016.82","article-title":"Psoriasis","volume":"2","author":"Greb","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.apsb.2019.11.006_bib2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0190-9622(99)70112-X","article-title":"Psoriasis causes as much disability as other major medical diseases","volume":"41","author":"Rapp","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.apsb.2019.11.006_bib3","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/13543776.2016.1192129","article-title":"Small molecules and antibodies for the treatment of psoriasis: a patent review (2010\u20132015)","volume":"26","author":"Chiricozzi","year":"2016","journal-title":"Expert Opin Ther Pat"},{"issue":"Suppl 3","key":"10.1016\/j.apsb.2019.11.006_bib4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2133.2012.11208.x","article-title":"Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data","volume":"167","author":"Rustin","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.apsb.2019.11.006_bib5","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nrd4763","article-title":"The psoriasis drugs market","volume":"14","author":"Rizvi","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2019.11.006_bib6","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1146\/annurev.biochem.78.072407.103733","article-title":"Sphingosine 1-phosphate receptor signaling","volume":"78","author":"Rosen","year":"2009","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.apsb.2019.11.006_bib7","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.apsb.2014.12.009","article-title":"Bile acids and sphingosine-1-phosphate receptor 2 in hepatic lipid metabolism","volume":"5","author":"Kwong","year":"2015","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2019.11.006_bib8","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.pharmthera.2005.05.002","article-title":"FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors","volume":"108","author":"Chiba","year":"2005","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.apsb.2019.11.006_bib9","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1146\/annurev.immunol.23.021704.115628","article-title":"Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs","volume":"23","author":"Cyster","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.apsb.2019.11.006_bib10","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/1346-8138.14139","article-title":"Pathogenesis of psoriasis and development of treatment","volume":"45","author":"Ogawa","year":"2018","journal-title":"J Dermatol"},{"key":"10.1016\/j.apsb.2019.11.006_bib11","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3109\/09546634.2013.879093","article-title":"The role of IL-17 in psoriasis","volume":"26","author":"Malakouti","year":"2015","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.apsb.2019.11.006_bib12","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1177\/1203475416651605","article-title":"The role of IL-17 in the pathogenesis of psoriasis and update on IL-17 inhibitors for the treatment of plaque psoriasis","volume":"20","author":"AbuHilal","year":"2016","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.apsb.2019.11.006_bib13","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1046\/j.1365-2249.1997.d01-885.x","article-title":"The in\u00a0vivo induction of lymphocyte apoptosis in MRL-lpr\/lpr mice treated with FTY720","volume":"107","author":"Suzuki","year":"1997","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.apsb.2019.11.006_bib14","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s000110050608","article-title":"Effect of FTY720, a novel immunosuppressant, on adjuvant-induced arthritis in rats","volume":"49","author":"Matsuura","year":"2000","journal-title":"Inflamm Res"},{"key":"10.1016\/j.apsb.2019.11.006_bib15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/WNF.0b013e3181cbf825","article-title":"Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis","volume":"33","author":"Chun","year":"2010","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.apsb.2019.11.006_bib16","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/nrd3248","article-title":"Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis","volume":"9","author":"Brinkmann","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2019.11.006_bib17","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/S0140-6736(14)60803-5","article-title":"Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial","volume":"384","author":"Vaclavkova","year":"2014","journal-title":"The Lancet"},{"key":"10.1016\/j.apsb.2019.11.006_bib18","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/S0140-6736(14)61039-4","article-title":"Ponesimod\u2014a future oral therapy for psoriasis?.","volume":"384","author":"Ryan","year":"2014","journal-title":"The Lancet"},{"key":"10.1016\/j.apsb.2019.11.006_bib19","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1248\/bpb.b17-00939","article-title":"Validating a selective S1P1 receptor modulator Syl930 for psoriasis treatment","volume":"41","author":"Ji","year":"2018","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.apsb.2019.11.006_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2014.07.081","article-title":"Discovery of oxazole and triazole derivatives as potent and selective S1P1 agonists through pharmacophore-guided design","volume":"85","author":"Tian","year":"2014","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2019.11.006_bib21","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.apsb.2016.06.001","article-title":"Pharmacokinetics of H002, a novel S1PR1 modulator, and its metabolites in rat blood using liquid chromatography-tandem mass spectrometry","volume":"6","author":"Mi","year":"2016","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2019.11.006_bib22","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1039\/c3md00079f","article-title":"Design, synthesis and docking-based 3D-QSAR study of novel 2-substituted 2-aminopropane-1,3-diols as potent and selective agonists of sphingosine-1-phosphate 1 (S1P1) receptor","volume":"4","author":"Tian","year":"2013","journal-title":"MedChemComm"},{"key":"10.1016\/j.apsb.2019.11.006_bib23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/BF01517182","article-title":"Differential recovery of polymorphonuclear neutrophils, B and T cell subpopulations in the thymus, bone marrow, spleen and blood of mice following split-dose polychemotherapy","volume":"39","author":"Talmadge","year":"1994","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.apsb.2019.11.006_bib24","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1128\/MCB.00159-12","article-title":"The stress response mediator ATF3 represses androgen signaling by binding the androgen receptor","volume":"32","author":"Wang","year":"2012","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.apsb.2019.11.006_bib25","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.bcp.2014.04.010","article-title":"Development of a selective S1P1 receptor agonist, Syl930, as a potential therapeutic agent for autoimmune encephalitis","volume":"90","author":"Jin","year":"2014","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.apsb.2019.11.006_bib26","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1161\/01.CIR.0000152101.41037.AB","article-title":"KRP-203, a novel synthetic immunosuppressant, prolongs graft survival and attenuates chronic rejection in rat skin and heart allografts","volume":"111","author":"Shimizu","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.apsb.2019.11.006_bib27","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1021\/jm100181s","article-title":"2-Imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists","volume":"53","author":"Bolli","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2019.11.006_bib28","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nrd2356","article-title":"Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules","volume":"8","author":"Marsolais","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2019.11.006_bib29","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ijpharm.2016.07.043","article-title":"Mechanisms of imiquimod skin penetration","volume":"511","author":"Telo","year":"2016","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2019.11.006_bib30","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.apsb.2019.11.006_bib31","doi-asserted-by":"crossref","first-page":"7692024","DOI":"10.1155\/2016\/7692024","article-title":"T helper cell subsets in clinical manifestations of psoriasis","volume":"2016","author":"Diani","year":"2016","journal-title":"J Immunol Res"},{"key":"10.1016\/j.apsb.2019.11.006_bib32","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1124\/jpet.103.062828","article-title":"Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes","volume":"309","author":"Forrest","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.apsb.2019.11.006_bib33","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1136\/thoraxjnl-2011-200026","article-title":"Sphingosine-1-phosphate is increased in patients with idiopathic pulmonary fibrosis and mediates epithelial to mesenchymal transition","volume":"67","author":"Milara","year":"2012","journal-title":"Thorax"},{"key":"10.1016\/j.apsb.2019.11.006_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106792","article-title":"Knock out of S1P3 receptor signaling attenuates inflammation and fibrosis in bleomycin-induced lung injury mice model","volume":"9","author":"Murakami","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2019.11.006_bib35","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.pupt.2017.03.010","article-title":"FTY720 promotes pulmonary fibrosis when administered during the remodelling phase following a bleomycin-induced lung injury","volume":"44","author":"Gendron","year":"2017","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.apsb.2019.11.006_bib36","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1172\/JCI45403","article-title":"Engagement of S1P1-degradative mechanisms leads to vascular leak in mice","volume":"121","author":"Oo","year":"2011","journal-title":"J Clin Investig"},{"key":"10.1016\/j.apsb.2019.11.006_bib37","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/j.1476-5381.2012.02061.x","article-title":"The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate","volume":"167","author":"Gergely","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.apsb.2019.11.006_bib38","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1126\/science.1070238","article-title":"Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists","volume":"296","author":"Mandala","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.apsb.2019.11.006_bib39","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1600-6143.2005.00754.x","article-title":"The heart rate decrease caused by acute FTY720 administration is mediated by the G\u00a0protein-gated potassium channel I","volume":"5","author":"Koyrakh","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.apsb.2019.11.006_bib40","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1021\/jm901776q","article-title":"Removal of sphingosine 1-phosphate receptor-3 (S1P3) agonism is essential, but inadequate to obtain immunomodulating 2-aminopropane-1,3-diol S1P1 agonists with reduced effect on heart rate","volume":"53","author":"Hamada","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2019.11.006_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052985","article-title":"The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P1) and hypertension (S1P3) in rat","volume":"7","author":"Fryer","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2019.11.006_bib42","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1021\/ml300396r","article-title":"Discovery of BAF312 (siponimod), a potent and selective S1P receptor modulator","volume":"4","author":"Pan","year":"2013","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.apsb.2019.11.006_bib43","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1021\/ml100301k","article-title":"Discovery of CS-0777: a potent, selective, and orally active S1P1 agonist","volume":"2","author":"Nishi","year":"2011","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.apsb.2019.11.006_bib44","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1365-2249.2012.04669.x","article-title":"Efficacy and immunomodulatory actions of ONO-4641, a novel selective agonist for sphingosine 1-phosphate receptors 1 and 5, in preclinical models of multiple sclerosis","volume":"171","author":"Komiya","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.apsb.2019.11.006_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193236","article-title":"Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus","volume":"13","author":"Taylor Meadows","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2019.11.006_bib46","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/1346-8138.12367","article-title":"Mechanism of pathogenesis of imiquimod-induced skin inflammation in the mouse: a role for interferon-alpha in dendritic cell activation by imiquimod","volume":"41","author":"Ueyama","year":"2014","journal-title":"J Dermatol"},{"key":"10.1016\/j.apsb.2019.11.006_bib47","doi-asserted-by":"crossref","first-page":"24477","DOI":"10.1038\/srep24477","article-title":"Plasmacytoid dendritic cells orchestrate TLR7-mediated innate and adaptive immunity for the initiation of autoimmune inflammation","volume":"6","author":"Takagi","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2019.11.006_bib48","doi-asserted-by":"crossref","first-page":"4126","DOI":"10.4049\/jimmunol.1401842","article-title":"FTY720 abrogates collagen-induced arthritis by hindering dendritic cell migration to local lymph nodes","volume":"195","author":"Han","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.apsb.2019.11.006_bib49","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1172\/JCI28295","article-title":"Local application of FTY720 to the lung abrogates experimental asthma by altering dendritic cell function","volume":"116","author":"Idzko","year":"2006","journal-title":"J Clin Investig"},{"key":"10.1016\/j.apsb.2019.11.006_bib50","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1111\/j.1600-6143.2005.01085.x","article-title":"The sphingosine-1-phosphate receptor agonist FTY720 modulates dendritic cell trafficking in\u00a0vivo","volume":"5","author":"Lan","year":"2005","journal-title":"Am J Transplant"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383519308536?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383519308536?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T16:40:30Z","timestamp":1761928830000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383519308536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S2211383519308536"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2019.11.006","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel S1P1 modulator IMMH002 ameliorates psoriasis in multiple animal models","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2019.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}